1 active not recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Myeloblastic Leukemia: new trials by email Literature Review of Myeloblastic Leukemia trials Research Report on Myeloblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 - Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2024-07-10 | 2025-01-01 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor - Acute Lymphoblastic Leukemia, Myeloblastic Leukemia | Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 56 | 2022-08-23 | 2023-09-28 |
Leukemia, Biphenotypic, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Myelomonocytic, Juvenile (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Bone Marrow Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma (1) · Myelodysplastic-Myeloproliferative Diseases (1)
Abatacept (1) · Calcineurin Inhibitors (1) · Etoposide (1) · vedolizumab (1)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2)
Russia (2)